UAE first to approve oral therapy for rare autoimmune disorder

The UAE has become the first country in the world to approve an oral therapy for a rare autoimmune disorder.

The newly authorised drug, Rilzabrutinib, targets Immune Thrombocytopenia - a condition that affects just a few individuals per 100,000 worldwide.

Developed by global pharmaceutical company Sanofi, Rilzabrutinib is the first oral Bruton’s tyrosine kinase inhibitor to be approved for this condition.

The treatment works by restoring immune system balance and increasing platelet counts, offering patients faster relief and improved quality of life.

Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators.

Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE’s commitment to pioneering advanced therapies and strengthening its role as a regional leader in pharmaceutical innovation.

Emirates Drug Establishment approves world’s first oral therapy for immune thrombocytopenia#WamNews https://t.co/hPemiKqXIA pic.twitter.com/MZHZM3gTg6

— WAM English (@WAMNEWS_ENG) July 8, 2025